AmberGen seeks an experienced, energetic, highly motivated and creative scientist to join an expanding biotech company developing cutting edge technology in the field of spatial biology and mass spectrometric imaging. A successful candidate will have an opportunity to play a key role in the development and commercialization of pioneering mass spectrometric tissue imaging technology.
- Report directly to the Chief Scientific Officer; work with other science team members on development of AmberGen’s Mass Spectrometric tissue imaging technology and applications in clinical pathology/oncology.
- Conduct experiments on advanced MSI instrumentation including Bruker timsTOF
- Present research at conferences, co-author papers and develop grant proposals
- Work directly with customers on their application needs
- Graduate and/or post-doctoral experience in mass spectrometric imaging,
- Additional relevant areas of experience sought include immunohistochemistry (IHC), other tissue imaging modalities including fluoresence, Raman and FTIR, biochemistry and histopathology.
- Strong organizational abilities, meticulous laboratory skills, ability to work as part of a team,
- Compatibility with a small business environment including early-stage R&D, creativity and the ability to quickly adapt to new projects.
- Good communication skills
How to Apply:
The position is available immediately. AmberGen is an innovative and growing company which offers competitive benefits, an exciting work environment and an attractive location in the Greater Boston Area. Job responsibilities and salary will be commensurate with the applicant’s experience and skill level. AmberGen is an equal opportunity employer.
Please apply through the Online interface or send your résumé or CV (PDF preferred) to firstname.lastname@example.org using “2022 MSI Scientist” in the Subject line.
For more information, please contact:
About AmberGen, Inc.: AmberGen, Inc. is a privately held, Boston-area company founded in 1995 to commercialize pioneering photonic technology developed at Boston University’s Molecular Biophysics Laboratory and the Photonics Center. AmberGen’s development of proprietary peptide code photocleavable linkers (PC-Linker™) led to the early introduction of novel photocleavable reagents, such as PC-Biotin and PC-Phosphoramidites which underlie several major commercial proteomic and genomic technologies. The company’s mission is to innovate in the area of therapeutics and diagnostics by solving key problems that limit progress in medicine. AmberGen’s approach combines patented techniques in proteomics and light-based control of biomolecules. For more information, see www.ambergen.com.